Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €22.02 EUR
Change Today +0.51 / 2.37%
Volume 0.0
3A9 On Other Exchanges
Symbol
Exchange
Frankfurt
As of 9:31 AM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

alder biopharmaceuticals inc (3A9) Snapshot

Open
€22.15
Previous Close
€21.51
Day High
€23.12
Day Low
€22.02
52 Week High
01/15/15 - €26.96
52 Week Low
05/28/14 - €7.17
Market Cap
830.1M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
37.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALDER BIOPHARMACEUTICALS INC (3A9)

Related News

No related news articles were found.

alder biopharmaceuticals inc (3A9) Related Businessweek News

No Related Businessweek News Found

alder biopharmaceuticals inc (3A9) Details

Alder Biopharmaceuticals Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes various therapeutic antibodies in the United States and Australia. It is developing monoclonal antibodies comprising ALD403, which has completed Phase Ib proof-of-concept trials to target calcitonin gene-related peptide for the prevention of migraine; and Clazakizumab that has completed Phase IIb clinical trials that inhibits the pro-inflammatory cytokine interleukin-6 in the treatment of rheumatoid arthritis and psoriatic arthritis. The company also has preclinical programs in the discovery phase for various indications. Alder Biopharmaceuticals Inc. has a collaboration with Bristol-Myers Squibb Company for the development of Clazakizumab. Alder Biopharmaceuticals Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.

76 Employees
Last Reported Date: 08/5/14
Founded in 2002

alder biopharmaceuticals inc (3A9) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $420.0K
Co-Founder and Chief Scientific Officer
Total Annual Compensation: $376.9K
Senior Vice President of Translational Medici...
Total Annual Compensation: $368.5K
Chief Business Officer and Treasurer
Total Annual Compensation: $323.8K
Compensation as of Fiscal Year 2014.

alder biopharmaceuticals inc (3A9) Key Developments

Alder Biopharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Alder Biopharmaceuticals Inc. announced unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, loss from operations was $6,967,000 against $3,863,000 a year ago. Net loss was $6,942,000 against $3,875,000 a year ago. Net loss per share – diluted was $0.22 against $3.94 a year ago. The company reported total revenues of $6.4 million compared to $4.8 million for the same period a year ago. For the year, income from operations was $8,804,000 against $20,761,000 a year ago. Net income was $8,908,000 against net loss of $20,613,000 a year ago. Net income per share – diluted was $0.30 against net loss per share of $21.14 a year ago. Total revenues were $54.7 million compared to $18.8 million the same period last year. Increased revenues for both periods were due to the acceleration of recognition of previously deferred revenue as a result of the early termination of the license agreement with BMS for Clazakizumab.

Alder Biopharmaceuticals Inc. to Report Q4, 2014 Results on Mar 04, 2015

Alder Biopharmaceuticals Inc. announced that they will report Q4, 2014 results at 5:00 PM, Eastern Standard Time on Mar 04, 2015

Alder Biopharmaceuticals Inc., Q4 2014 Earnings Call, Mar 04, 2015

Alder Biopharmaceuticals Inc., Q4 2014 Earnings Call, Mar 04, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
3A9:GR €22.02 EUR +0.51

3A9 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 3A9.
View Industry Companies
 

Industry Analysis

3A9

Industry Average

Valuation 3A9 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALDER BIOPHARMACEUTICALS INC, please visit www.alderbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.